TOCA - Tocagen Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Tocagen Inc.

4242 Campus Point Court
Suite 500
San Diego, CA 92121
United States
858-412-8400
http://www.tocagen.com

SectorHealthcare
IndustryBiotechnology
Full-time employees85

Key executives

NameTitlePayExercisedYear born
Mr. Martin J. DuvallCEO & Director782.68kN/A1962
Mr. Thomas E. DarcyCo-Founder & Director35kN/A1951
Dr. Douglas J. JollyCo-Founder and Exec. VP of Research & Pharmaceutical Devel.416.87kN/A1948
Mr. Mark G. Foletta CPA, CPAExec. VP & CFO540.1kN/A1961
Dr. Harry E. GruberFounder, Adviser & DirectorN/AN/A1953
Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.

Corporate governance

Tocagen Inc.’s ISS governance QualityScore as of 29 July 2019 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more